Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study [0.03%]
芦可替尼乳膏治疗青少年轻至中度特应性皮炎的安全性和耐受性：一项为期一年的3期开放标签研究结果
Joel C Joyce,H Chih-Ho Hong,Dareen D Siri et al.
Joel C Joyce et al.
Background: Ruxolitinib cream (1.5%) has demonstrated efficacy and safety in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis. Objective: ...
Evaluating the Performance of Artificial Intelligence in Accurately Detecting Skin Cancer: An Umbrella Review of Systematic Reviews and Meta-analyses [0.03%]
人工智能准确检测皮肤癌性能的评估：系统评价和-meta分析的伞式评价
Jae Joon Jeon,Hayoon Chun,Judith Lee et al.
Jae Joon Jeon et al.
Background: Artificial intelligence technology is being widely developed in dermatology. However, there remains a lack of comprehensive data analyzing the diagnostic performance of artificial intelligence in skin cancer. ...
Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis [0.03%]
原发性和转移性皮肤黑色素瘤的基因组学：系统评价和-meta分析
Manh Duc Hoang,Thi Oanh Bui,Van Tu Dao et al.
Manh Duc Hoang et al.
Background: Melanoma is an aggressive skin cancer with limited durable responses despite therapeutic advances. Comprehensive characterization of genomic alterations may improve understanding of disease progression and inf...
Luca Rapparini,Michela Starace,Zoe Apalla et al.
Luca Rapparini et al.
Janus kinase inhibitors are increasingly used for the treatment of a wide range of dermatologic and non-dermatologic immune-mediated diseases, leading to growing interest in their safety profile, particularly with respect to cutaneous adver...
Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium [0.03%]
关于不同年龄段外生殖器银屑病护理的考虑因素：来自外生殖器银屑病健康联盟的一项改良德尔菲共识倡议
Michael Payette,Tina Bhutani,Melodie Young et al.
Michael Payette et al.
Background: Genital psoriasis remains underdiagnosed and undertreated despite its substantial impact on quality of life. The sensitive nature of genital involvement contributes to diagnostic delays, patient distress, and ...
Transforming Outcomes in Advanced Basal Cell Carcinoma: The Evolving Role of Systemic Therapy [0.03%]
晚期基底细胞癌的治疗转机：系统性治疗的角色变迁
Anna A L Massella Patsea,Babette J A Verkouteren,Klara Mosterd
Anna A L Massella Patsea
Advanced basal cell carcinoma (aBCC) is an uncommon but severe presentation of basal cell carcinoma, including those with extensive local invasion and metastasis. Curative local treatments are often not feasible for patients with aBCC and t...
High-Frequency Ultrasound in Hidradenitis Suppurativa: From Lesion Detection to Iconographic Lesion-Level Management [0.03%]
高频超声在汗腺炎中的应用：从病变检测到图象化病灶水平管理
Cláudia Fontan,Antonio Martorell,Cláudia Elise Ferraz et al.
Cláudia Fontan et al.
Hidradenitis suppurativa is a chronic recurrent inflammatory disease in which conventional clinical examination frequently underestimates subclinical extension and fails to distinguish between lesion types that carry different therapeutic i...
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis [0.03%]
关于阿布司替尼、巴瑞克替尼和优普利尤单抗治疗特应性皮炎真实世界有效性和安全性的系统评价和 meta 分析的更正通知
Amalie Thorsti Møller Rønnstad,Daniel Isufi,Christopher G Bunick et al.
Amalie Thorsti Møller Rønnstad et al.
Published Erratum
American journal of clinical dermatology. 2026 May 5. DOI:10.1007/s40257-026-01025-2 2026
Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE [0.03%]
中重度特应性皮炎患者使用阿布西替尼和杜匹妥尤单抗改善症状及提高生活质量的后验分析：JADE COMPARE 和 JADE DARE 研究结果
Gil Yosipovitch,Melinda J Gooderham,Sarina B Elmariah et al.
Gil Yosipovitch et al.
Background: Atopic dermatitis is a chronic immune-inflammatory skin disease that significantly impairs quality of life, with itch representing a key, but not exclusive, contributor to this burden. ...
Real-World Treatment with Lebrikizumab or Tralokinumab for Atopic Dermatitis: A 60-Week Retrospective Comparative Study [0.03%]
利布里珠单抗或トラロキニュマブ治疗特应性皮炎的真实世界研究：一项长达60周的回顾性比较研究
Teppei Hagino,Akihiko Uchiyama,Hidehisa Saeki et al.
Teppei Hagino et al.